FULC.US Fulcrum Therapeutics Inc

Healthcare Pharmaceuticals USA Stocks
3.77 USD
Close of Nov 14, 2026
2.83 15.74
Market cap
USD 288M
P/E
-
P/B
0.91x
ROE
-24.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is FULC.US undervalued?

Graham number

The Graham number of Fulcrum Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Fulcrum Therapeutics Inc fundamental analysis

No fundamental analysis for Fulcrum Therapeutics Inc yet.

Fulcrum Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan a…

Full company profile